AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.

No one should die of hepatitis C." "MAVYRET has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection," said Roopal ...